Executive Regulatory Briefings
Regulatory Intelligence for Senior Leadership
Complexity translated into strategic clarity.
Designed for Decision-Makers
Senior leaders are responsible for regulatory risk decisions but rarely have time for deep technical training. These briefings are designed specifically for that gap — delivering the regulatory intelligence executives need to make sound strategic decisions, without the technical depth that belongs in the quality department. Each briefing is customized to your industry, your current regulatory environment, and the specific decisions your leadership team is facing.
Who this is for
CEOs, COOs, CFOs, board members, general counsel, and other senior leaders at companies operating in FDA-regulated industries. Particularly valuable during periods of regulatory change, M&A due diligence, investor preparation, or when entering new regulated categories.
Briefing Topics
- Current FDA enforcement priorities and what they mean for your business
- Regulatory risk assessment — where your organization is exposed and how to quantify it
- New and proposed regulations affecting your product categories
- Competitive regulatory landscape — how your peers are navigating the same environment
- Regulatory due diligence for M&A — what to look for and what to ask
- Building a regulatory strategy that supports growth objectives
- Crisis preparedness — FDA warning letters, recalls, and enforcement actions
Briefing Formats
Executive Briefing
2–3 hour session for your leadership team. Structured as a presentation followed by facilitated discussion. Delivered in-person or virtually.
Board Presentation
Condensed regulatory risk overview designed for board-level audiences. Typically 45–60 minutes with Q&A. Prepared materials provided for board records.
Ongoing Advisory Retainer
Quarterly or monthly briefings keeping your leadership team current on regulatory developments relevant to your business. Includes written summaries and on-call access.
Regulatory Areas Addressed
- FDA strategic priorities and enforcement trends — updated quarterly
- FSMA implementation and ongoing rulemaking
- Dietary supplement regulatory developments — NDI notifications, structure/function claims
- Cannabis and hemp regulatory status — federal and state landscape
- International regulatory harmonization affecting US market access
Equip Your Leadership Team
Regulatory complexity shouldn't be a blind spot at the executive level. We prepare briefings tailored to your industry, your current situation, and the decisions your team needs to make. Contact us to discuss your needs.